DE69430317D1 - Wasserlösliche aktive sulfone von polyethylenglycolen - Google Patents

Wasserlösliche aktive sulfone von polyethylenglycolen

Info

Publication number
DE69430317D1
DE69430317D1 DE69430317T DE69430317T DE69430317D1 DE 69430317 D1 DE69430317 D1 DE 69430317D1 DE 69430317 T DE69430317 T DE 69430317T DE 69430317 T DE69430317 T DE 69430317T DE 69430317 D1 DE69430317 D1 DE 69430317D1
Authority
DE
Germany
Prior art keywords
peg
substances
water
soluble active
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430317T
Other languages
English (en)
Other versions
DE69430317T2 (de
Inventor
Milton Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shearwater Corp filed Critical Shearwater Corp
Publication of DE69430317D1 publication Critical patent/DE69430317D1/de
Application granted granted Critical
Publication of DE69430317T2 publication Critical patent/DE69430317T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/321Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/326Polymers modified by chemical after-treatment with inorganic compounds containing sulfur
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent
DE69430317T 1993-11-12 1994-11-14 Wasserlösliche aktive sulfone von polyethylenglycolen Expired - Lifetime DE69430317T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/151,481 US5446090A (en) 1993-11-12 1993-11-12 Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
PCT/US1994/013013 WO1995013312A1 (en) 1993-11-12 1994-11-14 Water soluble active sulfones of poly(ethylene glycol)

Publications (2)

Publication Number Publication Date
DE69430317D1 true DE69430317D1 (de) 2002-05-08
DE69430317T2 DE69430317T2 (de) 2002-10-02

Family

ID=22538958

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430317T Expired - Lifetime DE69430317T2 (de) 1993-11-12 1994-11-14 Wasserlösliche aktive sulfone von polyethylenglycolen

Country Status (26)

Country Link
US (6) US5446090A (de)
EP (2) EP0728155B1 (de)
JP (1) JP3114998B2 (de)
KR (1) KR100225746B1 (de)
CN (1) CN1085689C (de)
AT (1) ATE215577T1 (de)
AU (1) AU687937B2 (de)
BG (1) BG63399B1 (de)
BR (1) BR9408048A (de)
CA (1) CA2176203C (de)
CZ (1) CZ295640B6 (de)
DE (1) DE69430317T2 (de)
DK (1) DK0728155T3 (de)
EE (1) EE03448B1 (de)
ES (1) ES2173943T3 (de)
FI (1) FI117441B (de)
HK (1) HK1042312A1 (de)
HU (1) HU225649B1 (de)
NO (1) NO315377B1 (de)
NZ (1) NZ276313A (de)
PL (1) PL180149B1 (de)
RO (2) RO121855B1 (de)
RU (1) RU2176253C2 (de)
SK (1) SK284527B6 (de)
UA (1) UA58481C2 (de)
WO (1) WO1995013312A1 (de)

Families Citing this family (440)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
HU230160B1 (hu) 1996-02-09 2015-09-28 Swedish Orphan Biovitrum Ab (Publ) Interleukin-I inhibitort és kontrollált felszabadulású polimerként hialuronant tartalmazó készítmények
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6566406B1 (en) * 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
AU4648697A (en) * 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6072040A (en) 1996-10-15 2000-06-06 Medical Analysis Systems, Inc. Stabilized conjugates of uncomplexed subunits of multimeric proteins
EP2002846B1 (de) 1996-12-06 2017-01-25 Amgen Inc. Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten
PT942740E (pt) 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
US6743248B2 (en) 1996-12-18 2004-06-01 Neomend, Inc. Pretreatment method for enhancing tissue adhesion
US6371975B2 (en) 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US20040176801A1 (en) * 1997-03-12 2004-09-09 Neomend, Inc. Pretreatment method for enhancing tissue adhesion
US20030191496A1 (en) * 1997-03-12 2003-10-09 Neomend, Inc. Vascular sealing device with microwave antenna
AU7282698A (en) * 1997-05-15 1998-12-08 Theratech, Inc. Targeted delivery to t lymphocytes
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
WO1999011202A1 (en) * 1997-09-05 1999-03-11 Icet, Inc. Biomimetic calcium phosphate implant coatings and methods for making the same
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル,コーポレイション 近位の反応性基を持つポリ(エチレングリコール)誘導体
JP2002507426A (ja) 1998-03-26 2002-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー アミノ酸置換を有するセリンプロテアーゼ変異体
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
US6458147B1 (en) 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
AU764144B2 (en) * 1998-08-28 2003-08-14 Gryphon Therapeutics, Inc. Polyamide chains of precise length, methods to manufacture them and their conjugates
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
BR9914023A (pt) 1998-09-22 2001-06-26 Procter & Gamble Composição de esfregão e de máscara da pele de tratamento pessoal e processo para umedecimento da pele
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6830756B2 (en) * 1998-11-06 2004-12-14 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6899889B1 (en) 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US6949114B2 (en) 1998-11-06 2005-09-27 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
MXPA01007777A (es) 1999-02-01 2003-10-06 Eidgenoess Tech Hochschule Bio-materiales formadas por reaccion de adicion nucleofila a grupos insaturados conjugados.
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2000078285A1 (en) * 1999-06-18 2000-12-28 University Of Medicine And Dentistry Of New Jersey Controlled release of therapeutics by in-situ entrapment by matrix cross-linking
CZ2002212A3 (cs) 1999-07-22 2002-07-17 The Procter & Gamble Company Varianty subtilisinové proteasy mající aminokyselinové substituce v definovaných epitopových oblastech
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CZ2002171A3 (cs) 1999-07-22 2002-06-12 The Procter & Gamble Company Proteinázový konjugát, čistící prostředek a prostředek osobní péče
JP2003505067A (ja) 1999-07-22 2003-02-12 ザ、プロクター、エンド、ギャンブル、カンパニー 特定のエピトープ領域にアミノ酸欠失及び置換を有するサブチリシンプロテアーゼの変異体
US7008635B1 (en) * 1999-09-10 2006-03-07 Genzyme Corporation Hydrogels for orthopedic repair
US6303119B1 (en) 1999-09-22 2001-10-16 The Procter & Gamble Company Personal care compositions containing subtilisin enzymes bound to water insoluble substrates
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
JP2003533682A (ja) 2000-05-15 2003-11-11 テカン・トレーディング・アクチェンゲゼルシャフト 双方向流動遠心ミクロ流体装置
ES2290142T3 (es) * 2000-05-16 2008-02-16 Bolder Biotechnology, Inc. Metodos para replegamiento de proteinas que contiene residuos de cisteina libre.
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
MXPA03000310A (es) * 2000-07-12 2004-12-13 Gryphon Therapeutics Inc Quimiocinas sinteticas bioactivas, modificadas con polimeros y metodos para su elaboracion y uso.
EP1318827A4 (de) * 2000-09-08 2005-09-14 Gryphon Therapeutics Inc Durch polymere veränderte synthetische proteine
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1355965B1 (de) * 2000-10-19 2012-09-19 Ecole Polytechnique Fédérale de Lausanne (EPFL) Verfahren zur herstellung von blockcopolymeren für multifunktionelle selbstorganisierende systeme
AU2002220002B2 (en) 2000-10-31 2006-12-14 Evonik Corporation Methods and compositions for enhanced delivery of bioactive molecules
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
DE60232434D1 (de) 2001-02-27 2009-07-09 Maxygen Aps Neue interferon-beta-ähnliche moleküle
US20030044468A1 (en) * 2001-03-20 2003-03-06 Francesco Cellesi Two-phase processing of thermosensitive polymers for use as biomaterials
US6538104B2 (en) * 2001-04-27 2003-03-25 Medical Analysis Systems, Inc. Stabilization of cardiac troponin I subunits and complexes
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
CA2457876C (en) * 2001-08-22 2011-10-11 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
EP2305311A3 (de) 2001-10-10 2011-07-20 BioGeneriX AG Glykokonjugation von Peptiden
ES2556338T3 (es) 2001-10-10 2016-01-15 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CA2462819A1 (en) * 2001-11-23 2003-05-30 Simon Fredriksson Method and kit for proximity probing with multivalent proximity probes
RS55578B1 (sr) * 2002-01-18 2017-06-30 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
US20030179692A1 (en) * 2002-03-19 2003-09-25 Yoshitaka Ohotomo Storage medium
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1941867T3 (da) 2002-06-07 2012-01-02 Dyax Corp Polypeptid med modificeret Kunitz domæne
PL211175B1 (pl) 2002-06-21 2012-04-30 Novo Nordisk Healthcare Ag Koniugat polipeptydu czynnika VII, sposób wytwarzania takiego koniugatu, zawierający taki koniugat preparat farmaceutyczny oraz zastosowanie takiego koniugatu
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
CA2497777A1 (en) * 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
KR20050083678A (ko) * 2002-09-05 2005-08-26 더 제너럴 하스피탈 코포레이션 아시알로-인터페론과 간암의 치료
WO2004022629A2 (en) 2002-09-09 2004-03-18 Nektar Therapeutics Al, Corporation Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
CN1312279C (zh) * 2002-11-07 2007-04-25 连云港新阳医药有限公司 聚乙二醇修饰门冬酰胺酶的制备方法
CA2511815A1 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
NZ541124A (en) * 2002-12-26 2008-08-29 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
EP1616003A4 (de) * 2002-12-30 2007-06-20 Gryphon Therapeutics Inc Wasserlösliche thioester- und selenoesterverbindungen sowie verfahren zur herstellung und verwendung davon
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
ES2352337T5 (es) * 2003-01-06 2017-08-11 Nektar Therapeutics Derivados tiol-selectivos de un polimero soluble en agua
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2509939C (en) * 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
AU2004218354B2 (en) * 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
AU2004227937B2 (en) * 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2521381C (en) 2003-04-11 2020-05-26 Kenneth Hinds Method for preparation of site-specific protein conjugates
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
ES2380093T3 (es) 2003-05-09 2012-05-08 Biogenerix Ag Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2341960T3 (es) 2003-07-22 2010-06-30 Nektar Therapeutics Procedimientos para preparar polimeros funcionalizados a partir de alcoholes polimericos.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
PT1663281E (pt) * 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
PL1675622T3 (pl) 2003-09-17 2017-11-30 Nektar Therapeutics Proleki na bazie wieloramiennego polimeru
EP1675620B1 (de) * 2003-10-09 2019-05-08 Ambrx, Inc. Polymerderivate
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
EP1675871A2 (de) 2003-10-10 2006-07-05 Xencor Inc. Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
WO2005044836A2 (de) 2003-11-05 2005-05-19 Genovoxx Gmbh Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
ES2445948T3 (es) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
EP1694301A4 (de) 2003-12-02 2009-11-18 Cytimmune Sciences Inc Verfahren und zusammensetzungen zur herstellung von monoklonalen antikörpern
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
CN101072789B (zh) * 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
US20050175584A1 (en) * 2004-01-28 2005-08-11 Paciotti Giulio F. Functionalized colloidal metal compositions and methods
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
WO2005074524A2 (en) * 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
KR100580644B1 (ko) * 2004-02-16 2006-05-16 삼성전자주식회사 생물분자를 고체 기판상에 비공유적으로 고정화 하는 방법및 그에 의하여 제조되는 마이크로어레이
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
MXPA06010505A (es) * 2004-03-15 2006-12-19 Nektar Therapeutics Al Corp Composiciones y conjugados, basados en polimeros, de inhibidores de ingreso de vih.
JP2007531715A (ja) * 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合fgf−21化合物
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP2359842A1 (de) 2004-07-14 2011-08-24 University of Utah Research Foundation Netrin verwandten zusammensetzungen und verwendungen
EP1771573A4 (de) * 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
EP2301963A1 (de) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptidverbindungen zur Hemmung von Angiogenese und Tumorwachstum
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7612153B2 (en) * 2004-10-25 2009-11-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
CN101111267B (zh) 2004-12-21 2012-12-05 尼克塔治疗公司 稳定的聚合物巯基试剂
CN103290084A (zh) 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
EP1828224B1 (de) 2004-12-22 2016-04-06 Ambrx, Inc. Zusammensetzungen mit, verfahren mit und verwendungen von nichtnatürlichen aminosäuren und polypeptiden
JP4990792B2 (ja) * 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−tRNAシンテターゼの組成物およびこの使用
MX2007007587A (es) * 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
AU2006213822B2 (en) * 2005-02-09 2011-05-26 Covidien Lp Synthetic sealants
EP1868652A2 (de) 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1885403B1 (de) * 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethylenglykol)-Konjugate von Lysostaphin
KR20080013878A (ko) 2005-04-18 2008-02-13 노보 노르디스크 에이/에스 Il-21 변이체
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2608311C (en) 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
JP5216580B2 (ja) * 2005-05-25 2013-06-19 ノヴォ ノルディスク アー/エス グリコペグ化第ix因子
EP1891141B1 (de) * 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AU2006259525B2 (en) 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
EP1926768B1 (de) 2005-07-18 2011-09-14 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
CA2626522A1 (en) * 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
SG170116A1 (en) * 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8293869B2 (en) * 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
US7743730B2 (en) * 2005-12-21 2010-06-29 Lam Research Corporation Apparatus for an optimized plasma chamber grounded electrode assembly
EP1981525B1 (de) 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Verlängerte freisetzung von neuregulin für verbesserte herzfunktion
CN101400363B (zh) 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
MX2008010841A (es) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Polimeros degradables segmentados y conjugados hechos de los mismos.
EP2004231A4 (de) 2006-04-07 2013-07-10 Nektar Therapeutics Konjugate eines anti-tnf-alpha-antikörpers
EP2574624A1 (de) 2006-04-20 2013-04-03 Amgen Inc. GLP-1-Verbindungen
US7560588B2 (en) * 2006-04-27 2009-07-14 Intezyne Technologies, Inc. Poly(ethylene glycol) containing chemically disparate endgroups
CN101484576A (zh) 2006-05-24 2009-07-15 诺沃-诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
JP2009541333A (ja) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
US8242179B2 (en) * 2006-06-23 2012-08-14 Surmodics, Inc. Hydrogel-based joint repair system and method
EP2049151A4 (de) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
JP2009544327A (ja) * 2006-07-21 2009-12-17 ノヴォ ノルディスク アー/エス O−結合型グリコシル化配列によるペプチドのグリコシル化
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス,インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーtrna
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス ポリペプチドコンジュゲートの精製方法
LT2068907T (lt) * 2006-10-04 2018-01-10 Novo Nordisk A/S Glicerolio sujungti pegilinti sacharidai ir glikopeptidai
AU2007343796A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
KR20090110295A (ko) 2006-11-22 2009-10-21 에드넥서스, 어 브리스톨-마이어스 스퀴브 알&디 컴파니 Igf-ir을 포함하는 티로신 키나제 수용체에 대한 공학처리된 단백질에 기반한 표적화 치료제
KR101441709B1 (ko) * 2006-11-30 2014-09-18 넥타르 테라퓨틱스 중합체 컨쥬게이트의 제조 방법
PT2121751T (pt) 2006-12-08 2017-04-18 Lexicon Pharmaceuticals Inc Anticorpos monoclonais contra angptl3
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
EP2117603A2 (de) * 2006-12-19 2009-11-18 Bracco International B.V. Targeting und therapeutische verbindungen und gasgefüllte mikrovesikel mit diesen verbindungen
EP2097140B1 (de) 2006-12-20 2012-09-26 Arkema Inc. Polymer-verkapselung und/oder bindung
EP2121754B1 (de) 2007-01-18 2015-02-11 Eli Lilly and Company Pegyliertes amyloid beta fab
ES2558928T3 (es) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Péptidos p53 estabilizados y usos de los mismos
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 g―csf를 이용하는 치료 방법
ES2381639T3 (es) 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
AU2008247815B2 (en) * 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008153745A2 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーratiopharm GmbH ヌクレオチド糖の改良製造法
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 白介素-22在治疗脂肪肝中的应用
KR20100046185A (ko) * 2007-08-09 2010-05-06 다이이찌 산쿄 가부시키가이샤 데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
AU2008302035A1 (en) * 2007-09-21 2009-03-26 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
JP2010540681A (ja) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ,インコーポレーテッド リボヌクレアーゼに基づく治療のための組成物及び方法
EP2214716B1 (de) * 2007-10-23 2021-11-17 Nektar Therapeutics Auf hydroxyapatite gezielrichtete multiarm polymere und daraus hergestellte konjugate
WO2009062151A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
US20090123519A1 (en) * 2007-11-12 2009-05-14 Surmodics, Inc. Swellable hydrogel matrix and methods
WO2009064459A2 (en) * 2007-11-12 2009-05-22 Intradigm Corporation Heterobifunctional polyethylene glycol reagents
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20090226531A1 (en) * 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
CA3096629A1 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EA019289B1 (ru) 2008-04-21 2014-02-28 Тайджен Байотекнолоджи Ко., Лтд. Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP2293818B1 (de) * 2008-05-16 2021-04-28 Nektar Therapeutics Konjugate aus butyrylcholinesterase und eines polymers
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
CN102099058B (zh) * 2008-07-21 2014-10-22 宝力泰锐克斯有限公司 用于缀合生物分子的新试剂和方法
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
WO2010033205A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
EP2344199A1 (de) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer-konjugate von thymosin-alpha1-peptiden
EP2334334A1 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von nesiritid-peptiden
WO2010033218A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033221A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010033222A2 (en) * 2008-09-19 2010-03-25 Netkar Therapeutics Polymer conjugates of ziconotide peptides
WO2010033224A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
CN102224238B (zh) 2008-09-26 2015-06-10 Ambrx公司 非天然氨基酸复制依赖性微生物和疫苗
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ,インコーポレーテッド 治療用リボヌクレアーゼ
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
SG172064A1 (en) 2008-12-09 2011-07-28 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010080720A2 (en) 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
WO2010100430A1 (en) * 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
RS56496B1 (sr) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Kompozicije hemoglobina
CA2770149A1 (en) 2009-08-05 2011-02-10 Pieris Ag Controlled release formulations of lipocalin muteins
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
EP2494073B1 (de) 2009-10-26 2017-11-29 AGCT GmbH Konjugate von nukleotiden und methoden zu deren anwendung
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
CN102161754B (zh) * 2010-02-13 2012-06-13 华中科技大学同济医学院附属协和医院 枝化状聚乙二醇衍生物的功能化修饰方法
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ, インコーポレイテッド システイニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ, インコーポレイテッド アラニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
WO2011139854A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2566495B1 (de) 2010-05-03 2017-03-01 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ, インコーポレイテッド メチオニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (de) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Vla4のポリペプチド阻害剤
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2571896A4 (de) 2010-05-17 2014-01-08 Cebix Inc Pegyliertes c-peptid
JP6027965B2 (ja) 2010-05-17 2016-11-16 エータイアー ファーマ, インコーポレイテッド ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2011153277A2 (en) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CA2806058C (en) 2010-07-20 2016-09-13 Halozyme, Inc. Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects
TWI707926B (zh) 2010-07-30 2020-10-21 瑞士商愛爾康公司 可易於使用之聚矽氧水凝膠隱形鏡片
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2608801B1 (de) 2010-08-25 2019-08-21 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
AU2011325990C1 (en) 2010-11-12 2017-06-08 Nektar Therapeutics Conjugates of an IL-2 moiety and a polymer
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
SG189982A1 (en) 2010-11-24 2013-06-28 Lexicon Pharmaceuticals Inc Antibodies to notum pectinacetylesterase
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
EP2654795B1 (de) 2010-12-21 2018-03-07 Nektar Therapeutics Mehrarmige polymer prodrug-konjugate aus verbindungen auf pemetrexed-basis
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
AP2013007173A0 (en) 2011-03-16 2013-10-31 Amgen Inc Potent and selective inhibitors of NAV1.3 and NAV1.7
EP2709669A1 (de) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Verfahren zur aufrechterhaltung der pegylierung von polypeptiden
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
EP2720722A4 (de) 2011-06-16 2014-12-03 Univ Hong Kong Science & Techn Molekül mit mehreren vinylsulfonen
EP2720712B1 (de) 2011-06-17 2016-03-02 Halozyme, Inc. Stabile formulierungen eines hyaluronan-abbauenden enzyms
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2012174480A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN104093415B (zh) 2011-10-24 2017-04-05 哈洛齐梅公司 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
AU2012347926B2 (en) 2011-12-05 2018-03-15 Incept, Llc Medical organogel processes and compositions
EP2858661B1 (de) 2011-12-29 2020-04-22 Dana-Farber Cancer Institute, Inc. Stabilisierte antivirale fusionsspiralen
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
KR20140123571A (ko) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 자가면역 및 염증성 질환의 치료를 위한 히스티딜­trna 신테타제
TR201802761T4 (tr) 2012-03-30 2018-03-21 Univ Oklahoma Yüksek molekül ağırlıklı heparosan polimerler ve bunların üretimine ve kullanımına yönelik metotlar.
EP2838577B1 (de) 2012-04-02 2019-02-27 SurModics, Inc. Hydrophile polymerbeschichtungen für medizinische artikel mit einem visualisierungsteil
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
KR102163408B1 (ko) 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CN109503714A (zh) 2012-06-21 2019-03-22 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
CN105051065A (zh) 2012-06-22 2015-11-11 索伦托治疗有限公司 与ccr2结合的抗原结合蛋白
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
HUE045227T2 (hu) 2012-08-31 2019-12-30 Sutro Biopharma Inc Azido csoportot tartalmazó módosított aminosavak
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2916835A4 (de) 2012-11-12 2016-07-27 Redwood Bioscience Inc Verbindungen und verfahren zur herstellung eines konjugats
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1.7之強效及選擇性抑制劑
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
US10308926B2 (en) 2013-03-15 2019-06-04 Dana-Farber Cancer Institute, Inc. Stablized EZH2 peptides
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
CA2906740A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ph20玻尿酸酶變異體及其用途
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015073758A1 (en) 2013-11-15 2015-05-21 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CA2948864C (en) 2014-05-14 2023-10-17 Karl E. Griswold Deimmunized lysostaphin and methods of use
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
EP3646879B1 (de) 2014-08-12 2024-04-03 Massachusetts Institute Of Technology Synergistische tumorbehandlung mit integrin-bindendem fc-fusionsprotein und ein immun-checkpoint inhibitor
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
SG11201701384XA (en) 2014-10-14 2017-03-30 Polytherics Ltd Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
KR102513926B1 (ko) * 2014-10-24 2023-03-23 폴리테릭스 리미티드 접합체 및 접합 시약
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP3229851A4 (de) 2014-12-09 2018-08-01 Tangible Science LLC Beschichtung einer medizinischen vorrichtung mit biokompatibler schicht
WO2016149613A2 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
AU2016287754B2 (en) 2015-07-02 2021-02-25 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
EP3341008A4 (de) 2015-08-28 2019-05-15 Dana-Farber Cancer Institute, Inc. An bfl-1 bindende peptide
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3013051A1 (en) 2016-01-29 2017-08-03 Heyue Zhou Antigen binding proteins that bind pd-l1
US20170247423A1 (en) 2016-02-29 2017-08-31 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
US10421785B2 (en) 2016-04-11 2019-09-24 Bar-Ilan University Delta receptor agonist peptides and use thereof
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
WO2018017922A2 (en) 2016-07-22 2018-01-25 Massachusetts Institute Of Technology Selective bfl-1 peptides
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
EP3503924B1 (de) 2016-08-26 2022-12-14 Dana-Farber Cancer Institute, Inc. Bcl-w-polypeptide und mimetika zur behandlung oder prävention von chemotherapieinduzierter peripherer neuropathie und hörverlust
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
WO2018172503A2 (en) 2017-03-24 2018-09-27 Basf Se Liquid laundry detergent comprising modified saccharide or polysaccharide
BR112019027583A2 (pt) 2017-06-22 2020-10-06 Catalyst Biosciences, Inc. polipeptídeos de serina protease 1 tipo membrana (mtsp-1) modificados e métodos de uso
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
EP3684811A2 (de) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
EP3688007A1 (de) 2017-09-27 2020-08-05 The University of York Biokonjugation von polypeptiden
EP3724216A1 (de) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Durch stabilisiertes peptid vermittelter zielgerichteter proteinabbau
EP3737404A1 (de) 2017-12-15 2020-11-18 Dana Farber Cancer Institute, Inc. Selektives targeting von apoptose-proteinen durch strukturstabilisierte und/oder cysteinreaktive noxa-peptide
EP3732254A4 (de) 2017-12-26 2021-12-22 Becton, Dickinson and Company Tiefe uv-erregbare wassersolvatisierte polymerfarbstoffe
EP3749678A1 (de) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Zellpermeable, geheftete peptidmodule zur zellulären abgabe
EP3765852A1 (de) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Stabilisierte peptide für den nachweis von biomarkern
US10844228B2 (en) 2018-03-30 2020-11-24 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
JP2021535140A (ja) 2018-08-28 2021-12-16 アンブルックス, インコーポレイテッドAmbrx, Inc. 抗cd3抗体葉酸生物複合体およびその使用
SG11202102427XA (en) 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
WO2020060975A1 (en) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
EP3867265A1 (de) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
US20220075098A1 (en) * 2018-12-19 2022-03-10 Tangible Science, Inc. Systems and methods of treating a hydrogel-coated medical device
WO2020140101A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP3962933A1 (de) 2019-04-18 2022-03-09 Dana-Farber Cancer Institute, Inc. Selektives targeting von ubiquitin- und ubiquitin-ähnlichen e1-aktivierenden enzymen durch strukturell stabilisierte peptide
WO2020219323A1 (en) 2019-04-26 2020-10-29 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials
EP4077361A1 (de) 2019-12-16 2022-10-26 Dana-Farber Cancer Institute, Inc. Strukturstabilisierte oncolytische peptide und verwendungen davon
AU2020408070A1 (en) 2019-12-20 2022-06-09 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine Inc Vorgespannte il2-muteins-verfahren und -zusammensetzungen
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
EP4114431A2 (de) 2020-03-04 2023-01-11 Dana-Farber Cancer Institute, Inc. Antivirale, strukturell stabilisierte sars-cov-2 peptide und verwendungen davon
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021258205A1 (en) 2020-04-22 2022-10-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof
CA3179873A1 (en) 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
EP4199968A1 (de) 2020-08-20 2023-06-28 Ambrx, Inc. Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon
US20230330238A1 (en) 2020-10-14 2023-10-19 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
EP4240395A1 (de) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antivirale strukturell stabilisierte ebolaviruspeptide und verwendungen davon
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
IL311151A (en) 2021-09-08 2024-04-01 Dana Farber Cancer Inst Inc Structurally clamped antiviral SARS-COV-2 peptide-cholesterol conjugates and uses thereof
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784524A (en) * 1971-06-25 1974-01-08 Grace W R & Co Urethane/thioether-containing polyene composition and the reaction product thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH586739A5 (de) * 1973-10-17 1977-04-15 Hoechst Ag
US4134887A (en) * 1973-10-17 1979-01-16 Hoechst Aktiengesellschaft Phenyl-azo-phenyl dyestuffs
US4179387A (en) * 1974-03-12 1979-12-18 Fuji Photo Film Co., Ltd. Process for producing magnetic FE oxide
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE2607766C3 (de) * 1976-02-26 1978-12-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung von trägergebundenen biologisch aktiven Substanzen
US4228019A (en) * 1978-06-19 1980-10-14 Texaco Development Corp. Secondary recovery process
US4473693A (en) * 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4430260A (en) * 1979-02-27 1984-02-07 Lee Weng Y Penicillin-polyvinyl alcohol conjugate and process of preparation
US4296097A (en) * 1979-02-27 1981-10-20 Lee Weng Y Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor
US4241199A (en) * 1979-09-18 1980-12-23 Union Carbide Corporation Novel polyester diols
US4280979A (en) * 1979-09-18 1981-07-28 Union Carbide Corporation Copolymers, compositions, and articles, and methods for making same
JPS585320A (ja) * 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
US4973493A (en) * 1982-09-29 1990-11-27 Bio-Metric Systems, Inc. Method of improving the biocompatibility of solid surfaces
JPS59204144A (ja) * 1983-04-12 1984-11-19 Daikin Ind Ltd 新規含フッ素化合物およびその製法
SE470099B (sv) * 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
SE454885B (sv) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4616644A (en) * 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4883864A (en) * 1985-09-06 1989-11-28 Minnesota Mining And Manufacturing Company Modified collagen compound and method of preparation
US4983494A (en) * 1985-10-16 1991-01-08 Fuji Photo Film Co., Ltd. Image forming process including heating step
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4871785A (en) * 1986-08-13 1989-10-03 Michael Froix Clouding-resistant contact lens compositions
DE3628717A1 (de) * 1986-08-23 1988-02-25 Agfa Gevaert Ag Haertungsmittel fuer proteine, eine damit gehaertete bindemittelschicht und eine solche schicht enthaltendes fotografisches aufzeichnungsmaterial
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
DE3634525A1 (de) * 1986-10-10 1988-04-21 Miles Lab Testmittel und indikatoren zum nachweis von thiolgruppen und verfahren zu deren herstellung
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NL8800577A (nl) * 1988-03-08 1989-10-02 Stichting Tech Wetenschapp Werkwijze voor het aanbrengen van een bloedcompatibele bekleding op polyetherurethaanvormstukken.
GB8824592D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
DE69120821T2 (de) * 1990-08-31 1997-01-23 Univ Minnesota Polyethylenglykol-Derivate für Festphasenanwendungen
US5380536A (en) * 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
SE467308B (sv) * 1990-10-22 1992-06-29 Berol Nobel Ab Fast yta belagd med ett hydrofilt ytterskikt med kovalent bundna biopolymerer, saett att framstaella en saadan yta och ett konjugat daerfoer
RU2166955C2 (ru) * 1991-01-18 2001-05-20 Эмген Инк. Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
ES2199935T3 (es) * 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
DK52791D0 (da) * 1991-03-22 1991-03-22 Kem En Tec As Adsorptionsmatricer
DK130991D0 (da) * 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
CA2112992C (en) * 1991-07-04 2002-06-11 Allan O. F. Lihme Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
EP0622394A1 (de) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung

Also Published As

Publication number Publication date
US20050209416A1 (en) 2005-09-22
EP0728155A1 (de) 1996-08-28
ATE215577T1 (de) 2002-04-15
BR9408048A (pt) 1996-12-24
NO961918L (no) 1996-07-12
FI962004A0 (fi) 1996-05-10
FI962004A (fi) 1996-05-10
NZ276313A (en) 1997-04-24
HK1042312A1 (zh) 2002-08-09
JP3114998B2 (ja) 2000-12-04
ES2173943T3 (es) 2002-11-01
PL180149B1 (pl) 2000-12-29
EE03448B1 (et) 2001-06-15
US5446090A (en) 1995-08-29
CN1085689C (zh) 2002-05-29
CA2176203C (en) 2003-06-10
US6894025B2 (en) 2005-05-17
BG63399B1 (bg) 2001-12-29
UA58481C2 (uk) 2003-08-15
HU225649B1 (en) 2007-05-29
RU2176253C2 (ru) 2001-11-27
EE9600128A (et) 1997-04-15
SK60896A3 (en) 1997-04-09
PL314298A1 (en) 1996-09-02
US20040037801A1 (en) 2004-02-26
AU1054895A (en) 1995-05-29
US5900461A (en) 1999-05-04
HUP9601253A2 (en) 2001-06-28
CZ137596A3 (en) 1996-10-16
DK0728155T3 (da) 2002-07-29
JPH09508926A (ja) 1997-09-09
CN1137280A (zh) 1996-12-04
FI117441B (fi) 2006-10-13
WO1995013312A1 (en) 1995-05-18
DE69430317T2 (de) 2002-10-02
BG100568A (bg) 1996-12-31
KR960705869A (ko) 1996-11-08
US5739208A (en) 1998-04-14
NO315377B1 (no) 2003-08-25
EP0728155B1 (de) 2002-04-03
US20020150548A1 (en) 2002-10-17
RO121855B1 (ro) 2008-06-30
US6610281B2 (en) 2003-08-26
NO961918D0 (no) 1996-05-10
EP1176160A2 (de) 2002-01-30
KR100225746B1 (ko) 1999-10-15
HU9601253D0 (en) 1996-07-29
US7214366B2 (en) 2007-05-08
RO118434B1 (ro) 2003-05-30
CA2176203A1 (en) 1995-05-18
EP1176160A3 (de) 2004-03-03
AU687937B2 (en) 1998-03-05
CZ295640B6 (cs) 2005-09-14
SK284527B6 (sk) 2005-05-05

Similar Documents

Publication Publication Date Title
DE69430317D1 (de) Wasserlösliche aktive sulfone von polyethylenglycolen
CA2174325A1 (en) Non-antigenic branched polymer conjugates
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
CA2283939A1 (en) Non-antigenic branched polymer conjugates
DE68906366T2 (de) CD4-Polypeptidderivate.
DE69823055D1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
FR2710843B1 (fr) Composition d'organopolysiloxane d'aspect gélifié, sans gélifiant, utilisable en cosmétique et dermatologie.
BR9105822A (pt) Clatratos de peroxiacidos
ATE116135T1 (de) Einschlusskomplex von nimesulide mit cyclodextrinen.
DK0400914T3 (da) Landbrugsmæssige skumsammensætninger
MX9101393A (es) Uso de marcadores moleculares en la reproduccion de arboles
DE3853547D1 (de) Reversibel ausfällbare, wasserlösliche Polymerkonjugate, ihre Herstellung und Verwendung in der homogenen Katalyse.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEKTAR THERAPEUTICS AL,CORP., HUNTSVILLE, ALA., US

R082 Change of representative

Ref document number: 728155

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE

R081 Change of applicant/patentee

Ref document number: 728155

Country of ref document: EP

Owner name: NEKTAR THERAPEUTICS, US

Free format text: FORMER OWNER: NEKTAR THERAPEUTICS AL,CORP., HUNTSVILLE, US

Effective date: 20121113

R082 Change of representative

Ref document number: 728155

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE

Effective date: 20121113